ClinicalTrials.gg
CompletedNCT02446483Updated Nov 17, 2017Results posted

A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy Adults

A Phase 4 interventional study of Idiazole 20mg DR tabs and PARIET 20 mg DR tabs in Gastrointestinal Diseases, sponsored by GlaxoSmithKline. Completed at 1 site in Egypt. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-17.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Other

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Mar 2014, registered May 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is an open-label, randomized, single dose, two-sequence, two-period crossover study, separated by 7 days washout interval from the first study drug administration.

In this study, the bioavailability of Rabeprazole from Idiazole 20 milligram (mg) delayed release (DR) tablets and PARIET 20 mg DR tablets after a single oral dose administration of each to healthy adults under fasting conditions, will be investigated by determining the 90% confidence limits for the log-transformed ratio (Test product / Reference product) for the bioequivalence parameters. The influence of sequence, product and period effect will be tested by analysis of variance (ANOVA).

In this study a total of 60 subjects plus 1-4 additional subjects will be enrolled and split into two groups (Group A and B) of 30 each. For each subject, a total of 33 blood draws will be done and the volume of blood will not exceed 300 milliliters (mL) for the study.

PARIET is a registered trademark of EISAI Co. Limited.

02

Conditions studied

  • Gastrointestinal Diseases

Keywords

  • Idiazole 20mg
  • PARIET 20 mg
  • Rabeprazole
  • bioequivalence
03

In context

Gastrointestinal Diseases

549 studies on the registry are indexed under Gastrointestinal Diseases; 102 are open to participants now.

This study's enrollment of 60 is below the median of 80 across 388 interventional studies indexed under Gastrointestinal Diseases.

Browse Gastrointestinal Diseases studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female, age 18 to 55 years, inclusive.
  • Body weight within 10 percent of normal range according to the accepted normal values for (BMI).
  • Medical demographics without evidence of deviation from normal medical condition.
  • Results of clinical laboratory test are within the normal range or with a deviation that is not considered clinically significant by principal investigator.
  • Subject does not have allergy to the drugs under investigation.

Exclusion criteria

Exclusion Criteria:

  • Subjects with known allergy to the products tested.
  • Subjects whose values of were outside the accepted normal ranges.
  • Female subjects who were pregnant, nursing or taking pills.
  • Medical demographics with evidence of deviation from normal medical condition.
  • Results of laboratory tests which are clinically significant.
  • Acute infection within one week preceding first study drug administration.
  • History of drug or alcohol abuse.
  • Subject does not agree not to take any prescription or non-prescription drugs within two weeks before first study drug administration and until the end of the study.
  • Subject is on a special diet (for example subject is vegetarian).
  • Subject does not agree not to consume any beverages or foods containing methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to the study administration of either study period until donating the last sample in each respective period.
  • Subject does not agree not to consume any beverages or foods containing grapefruit 7 days prior to first study drug administration until the end of the study.
  • Subject has a history of severe diseases which have direct impact on the study. Participation in a bioequivalence study or in a clinical study within the last 6 weeks before first study drug administration.
  • Subject intends to be hospitalized within 6 weeks after first study drug administration.
  • Subjects who, through completion of this study, would have donated more than 500 mL of blood in 7 days, or 750 mL of blood in 30 days, 1000 mL in 90 days, 1250 mL in 120 days, 1500 mL in 180 days, 2000 mL in 270 days, 2500 mL of blood in 1 year.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Group A

    Thirty subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in treatment period 2.

    Drug: Idiazole 20mg DR tabs · Drug: PARIET 20 mg DR tabs

  • Experimental
    Group B

    Thirty subjects will receive a single oral dose of PARIET 20 mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of idiazole 20mg DR tabs under fasting condition in treatment period 2.

    Drug: Idiazole 20mg DR tabs · Drug: PARIET 20 mg DR tabs

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Maximal Measured Plasma Concentration (Cmax) After a Single Dose

    Plasma samples for pharmacokinetic (PK) analysis were drawn at indicated time points of each treatment period. Cmax was defined as maximal measured plasma concentration over the time span specified. Values were reported as Least Squares Geometric Means with respective Geometric Coefficient of Variation (% CV).

    Time frame: Pre-dose (0.00) and 0.50, 1.00, 1.50, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 4.33, 4.66, 5.00, 5.33, 5.66, 6.00, 8.00, 12.00 and 14.00 h post-dose in each treatment period.

  2. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) and Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-infinity)

    Plasma samples for PK analysis were drawn at indicated time points of each treatment period. AUC0-t was calculated by the linear trapezoidal method. AUC0-infinity was calculated as the sum of the AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant, where first-order elimination or terminal rate constant was calculated from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations. Values were reported as Least Squares Geometric Means with respective % CV.

    Time frame: Pre-dose (0.00) and 0.50, 1.00, 1.50, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 4.33, 4.66, 5.00, 5.33, 5.66, 6.00, 8.00, 12.00 and 14.00 h post-dose in each treatment period.

Secondary outcomes

  1. Time of the Maximum Plasma Concentration (T-max) and Terminal Half-life (T-half)

    Plasma samples for PK analysis were drawn at indicated time points of each treatment period. If the maximum value occurs at more than one point T-max was defined as the first time point with this value. The elimination or terminal half-life was calculated by dividing 0.693 (natural logarithm of 2) with b obtained as the slope of the linear regression of the logarithmically transformed plasma concentrations versus time in the terminal period of the plasma curve.

    Time frame: Pre-dose (0.00) and 0.50, 1.00, 1.50, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 4.33, 4.66, 5.00, 5.33, 5.66, 6.00, 8.00, 12.00 and 14.00 h post-dose in each treatment period.

  2. Apparent First-order Elimination or Terminal Rate Constant

    Plasma samples for PK analysis were drawn at indicated time points of each treatment period. Apparent first-order elimination or terminal rate constant calculated from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations.

    Time frame: Pre-dose (0.00) and 0.50, 1.00, 1.50, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 4.33, 4.66, 5.00, 5.33, 5.66, 6.00, 8.00, 12.00 and 14.00 h post-dose in each treatment period

07

Results

Posted Jun 14, 2017

Participant flow

The study was planned on 60 adult healthy male and female participants, aged 18 to 55 years, at a single site of Egypt from 30 January 2014 to 27 October 2014. During each study period participants received test (treatment A- rabeprazole tablet) and reference (treatment B-rabeprazole tablet) products.

Period 1: Intervention Period 1
Participant flow — Period 1: Intervention Period 1
MilestoneTreatment A-rabeprazole 20mg,Then Treatment B-rabeprazole 20mgTreatment B-rabeprazole 20mg,Then Treatment A-rabeprazole 20mg
Started3030
Completed3030
Not completed00
Period 2: Washout Period (7 Days)
Participant flow — Period 2: Washout Period (7 Days)
MilestoneTreatment A-rabeprazole 20mg,Then Treatment B-rabeprazole 20mgTreatment B-rabeprazole 20mg,Then Treatment A-rabeprazole 20mg
Started3030
Completed3030
Not completed00
Period 3: Intervention Period 2
Participant flow — Period 3: Intervention Period 2
MilestoneTreatment A-rabeprazole 20mg,Then Treatment B-rabeprazole 20mgTreatment B-rabeprazole 20mg,Then Treatment A-rabeprazole 20mg
Started3030
Completed3030
Not completed00

Outcome measures

PrimaryMean Maximal Measured Plasma Concentration (Cmax) After a Single Dose

Plasma samples for pharmacokinetic (PK) analysis were drawn at indicated time points of each treatment period. Cmax was defined as maximal measured plasma concentration over the time span specified. Values were reported as Least Squares Geometric Means with respective Geometric Coefficient of Variation (% CV).

Time frame:
Pre-dose (0.00) and 0.50, 1.00, 1.50, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 4.33, 4.66, 5.00, 5.33, 5.66, 6.00, 8.00, 12.00 and 14.00 h post-dose in each treatment period.
Reported as:
Geometric mean · Nanogram per mL (ng/mL)
Mean Maximal Measured Plasma Concentration (Cmax) After a Single Dose
Nanogram per mL (ng/mL)Treatment A- Rabeprazole 20 mgTreatment B- Rabeprazole 20 mg
Mean Maximal Measured Plasma Concentration (Cmax) After a Single Dose543.78 ± 35.67530.34 ± 32.98
Statistical analysis
  • Treatment A- Rabeprazole 20 mg vs Treatment B- Rabeprazole 20 mg · Point estimate percent: 101.32 · 90% CI 95.81 to 107.15
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) and Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-infinity)

Plasma samples for PK analysis were drawn at indicated time points of each treatment period. AUC0-t was calculated by the linear trapezoidal method. AUC0-infinity was calculated as the sum of the AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant, where first-order elimination or terminal rate constant was calculated from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations. Values were reported as Least Squares Geometric Means with respective % CV.

Time frame:
Pre-dose (0.00) and 0.50, 1.00, 1.50, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 4.33, 4.66, 5.00, 5.33, 5.66, 6.00, 8.00, 12.00 and 14.00 h post-dose in each treatment period.
Reported as:
Geometric mean · ng.h/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) and Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-infinity)
ng.h/mLTreatment A- Rabeprazole 20 mgTreatment B- Rabeprazole 20 mg
AUC0-t916.07 ± 43.30922.52 ± 40.97
AUC0-infinity971.38 ± 41.98959.78 ± 42.21
Statistical analysis
  • Treatment A- Rabeprazole 20 mg vs Treatment B- Rabeprazole 20 mg · Point estimate percent: 98.71 · 90% CI 92.54 to 105.28
  • Treatment A- Rabeprazole 20 mg vs Treatment B- Rabeprazole 20 mg · Point estimate percent: 98.05 · 90% CI 91.81 to 104.71
SecondaryTime of the Maximum Plasma Concentration (T-max) and Terminal Half-life (T-half)

Plasma samples for PK analysis were drawn at indicated time points of each treatment period. If the maximum value occurs at more than one point T-max was defined as the first time point with this value. The elimination or terminal half-life was calculated by dividing 0.693 (natural logarithm of 2) with b obtained as the slope of the linear regression of the logarithmically transformed plasma concentrations versus time in the terminal period of the plasma curve.

Time frame:
Pre-dose (0.00) and 0.50, 1.00, 1.50, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 4.33, 4.66, 5.00, 5.33, 5.66, 6.00, 8.00, 12.00 and 14.00 h post-dose in each treatment period.
Reported as:
Median · h
Time of the Maximum Plasma Concentration (T-max) and Terminal Half-life (T-half)
hTreatment A- Rabeprazole 20 mgTreatment B- Rabeprazole 20 mg
Tmax2.66 (1.50 to 5.66)3.00 (1.50 to 8.00)
T-half2.79 (0.23 to 6.27)2.50 (0.70 to 5.73)
Statistical analysis
  • Treatment A- Rabeprazole 20 mg vs Treatment B- Rabeprazole 20 mg · Wilcoxon's Signed-Rank Test · p = 0.0029
SecondaryApparent First-order Elimination or Terminal Rate Constant

Plasma samples for PK analysis were drawn at indicated time points of each treatment period. Apparent first-order elimination or terminal rate constant calculated from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations.

Time frame:
Pre-dose (0.00) and 0.50, 1.00, 1.50, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 4.33, 4.66, 5.00, 5.33, 5.66, 6.00, 8.00, 12.00 and 14.00 h post-dose in each treatment period
Reported as:
Geometric mean · Per hour
Apparent First-order Elimination or Terminal Rate Constant
Per hourTreatment A- Rabeprazole 20 mgTreatment B- Rabeprazole 20 mg
Apparent First-order Elimination or Terminal Rate Constant0.35 ± 123.310.28 ± 46.12

Adverse events

Collected over Adverse events (AE) and serious adverse events (SAE) were reported through out the study (up to 11 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A- Rabeprazole 20 mg0/60 (0%)0/60 (0%)0/60 (0%)
Treatment B- Rabeprazole 20 mg0/60 (0%)0/60 (0%)0/60 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Treatment A-rabeprazole 20 mg + Treatment B-rabeprazole 20 mg
Mean30.72 ± 9.01
Sex: Female, Male
Sex: Female, Male(Participants)Treatment A-rabeprazole 20 mg + Treatment B-rabeprazole 20 mg
Female31
Male29
Region of Enrollment
Region of Enrollment(Participants)Treatment A-rabeprazole 20 mg + Treatment B-rabeprazole 20 mg
Egypt60
08

Study locations

1 site
  • GSK Investigational Site
    Cairo, Egypt
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Mar 2014, 0 months.

Results were first posted in Jun 2017, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2015
First posted
May 18, 2015
StartActual
Mar 19, 2014
Primary completionActual
Mar 26, 2014
CompletionActual
Mar 26, 2014
Results first posted
Jun 14, 2017
Last update
Nov 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02446483
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 18, 2015
Start date
Mar 19, 2014
Primary completion
Mar 26, 2014
Completion
Mar 26, 2014
Results posted
Jun 14, 2017
Last update
Nov 17, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion